GRITSTONE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8134 USD | +6.40% |
|
+10.43% | -60.13% |
| Apr. 15 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
| Apr. 02 | Top Midday Decliners | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 321.2 | 170.6 | 874.3 | 287.6 | 194.5 | 86.54 | - | - |
| Enterprise Value (EV) 1 | 193.4 | -0.4267 | 672.7 | 272.4 | 236.3 | 141.4 | 150.1 | 35.38 |
| P/E ratio | -3.19 x | -1.41 x | -13.5 x | -2.61 x | -1.7 x | -0.81 x | -0.93 x | -0.71 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 73.6 x | 42.3 x | 18.1 x | 14.4 x | 11.9 x | 2.32 x | 1.4 x | 1.88 x |
| EV / Revenue | 44.3 x | -0.11 x | 14 x | 13.7 x | 14.5 x | 3.78 x | 2.42 x | 0.77 x |
| EV / EBITDA | -2.08 x | 0 x | -9.77 x | -2.39 x | -1.79 x | -0.87 x | -0.98 x | -0.23 x |
| EV / FCF | -1.91 x | 0 x | -5.45 x | -2.24 x | -1.87 x | -0.92 x | -0.81 x | -0.14 x |
| FCF Yield | -52.3% | 21,705% | -18.3% | -44.7% | -53.4% | -108% | -123% | -738% |
| Price to Book | 2.43 x | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 35,806 | 43,307 | 67,988 | 83,366 | 95,342 | 106,399 | - | - |
| Reference price 2 | 8.970 | 3.940 | 12.86 | 3.450 | 2.040 | 0.8134 | 0.8134 | 0.8134 |
| Announcement Date | 3/11/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.365 | 4.037 | 48.21 | 19.94 | 16.34 | 37.37 | 61.93 | 45.98 |
| EBITDA 1 | -93.2 | -99.37 | -68.86 | -113.9 | -132 | -163.4 | -153.9 | -155.1 |
| EBIT 1 | -97.94 | -106 | -75.21 | -120.4 | -139.6 | -131.3 | -141.6 | -204 |
| Operating Margin | -2,243.76% | -2,626.13% | -155.99% | -603.8% | -854.26% | -351.47% | -228.62% | -443.6% |
| Earnings before Tax (EBT) 1 | -94.43 | -105.3 | -75.08 | -119.7 | -138.5 | -125.4 | -123.1 | -183.2 |
| Net income 1 | -94.43 | -105.3 | -75.08 | -119.7 | -138.5 | -125.4 | -123.1 | -183.2 |
| Net margin | -2,163.41% | -2,609.31% | -155.73% | -600.09% | -847.34% | -335.64% | -198.76% | -398.34% |
| EPS 2 | -2.810 | -2.790 | -0.9500 | -1.320 | -1.200 | -1.006 | -0.8740 | -1.140 |
| Free Cash Flow 1 | -101.2 | -92.62 | -123.4 | -121.8 | -126.2 | -153.4 | -185.4 | -261.2 |
| FCF margin | -2,318.08% | -2,294.2% | -255.99% | -610.77% | -772.27% | -410.51% | -299.38% | -568.14% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.614 | 3.064 | 7.191 | 5.471 | 3.021 | 4.262 | 2.443 | 1.955 | 1.565 | 10.38 | 3.261 | 3.261 | 10.13 | 17.28 | 75.5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -28.16 | -29.78 | -28.96 | -29.67 | -29.88 | -31.92 | -34.82 | -35.73 | -38.6 | -30.47 | -35.74 | -35.01 | -37.16 | -37.31 | -29 |
| Operating Margin | -1,077.08% | -972.06% | -402.77% | -542.28% | -988.98% | -748.92% | -1,425.13% | -1,827.52% | -2,466.71% | -293.47% | -1,096.19% | -1,073.65% | -366.78% | -215.99% | -38.41% |
| Earnings before Tax (EBT) 1 | -28.12 | -29.77 | -28.92 | -29.52 | -29.97 | -31.29 | -33.98 | -35.26 | -38.43 | -30.82 | -35.08 | -34.11 | -34.81 | -34.98 | -30.3 |
| Net income 1 | -28.12 | -29.77 | -28.92 | -29.52 | -29.97 | -31.29 | -33.98 | -35.26 | -38.43 | -30.82 | -35.08 | -34.11 | -34.81 | -34.98 | -30.3 |
| Net margin | -1,075.67% | -971.57% | -402.11% | -539.48% | -991.92% | -734.16% | -1,390.99% | -1,803.38% | -2,455.85% | -296.81% | -1,075.98% | -1,046.1% | -343.56% | -202.52% | -40.13% |
| EPS 2 | -0.3600 | -0.3600 | -0.3400 | -0.3400 | -0.3500 | -0.3000 | -0.3000 | -0.3100 | -0.3300 | -0.2600 | -0.3229 | -0.2729 | -0.2367 | -0.2417 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 3/10/22 | 5/5/22 | 8/4/22 | 11/3/22 | 3/9/23 | 5/11/23 | 8/9/23 | 11/8/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 41.8 | 54.8 | 63.6 | - |
| Net Cash position 1 | 128 | 171 | 202 | 15.2 | - | - | - | 51.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.3165 x | -0.3356 x | -0.413 x | - |
| Free Cash Flow 1 | -101 | -92.6 | -123 | -122 | -126 | -153 | -185 | -261 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 3.700 | - | - | - | - | - | - | - |
| Cash Flow per Share | -2.530 | - | - | - | - | - | - | - |
| Capex 1 | 16.2 | - | - | - | 4.57 | 5.5 | 6.6 | 7.9 |
| Capex / Sales | 370.52% | - | - | - | 27.97% | 14.72% | 10.66% | 17.18% |
| Announcement Date | 3/11/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/5/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.8134
USD
Average target price
5.167
USD
Spread / Average Target
+535.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.13% | 86.54M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- GRTS Stock
- Financials Gritstone bio, Inc.
